Use of Tocilizumab in COVID-19: A Systematic Review and Meta-Analysis of Current Evidence.

Cureus · 2020 · PMC7652362 · PMID 33178522

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

markedly significantno p-value reported

In terms of efficacy outcome, improved oxygen saturation (RR=1.13 [1.04, 1.65]; p=0.02; I 2 =0%) was reported to be markedly significant in tocilizumab patients when compared with the standard care group.

also in 476 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.